GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3, after its cobolimab candidate flunked a phase 3 trial in lung cancer.

The technical cooperation programme is the Agency’s primary mechanism for transferring nuclear technology to Member States, helping them to address key development priorities in areas such as health ...

Your browser does not support iframes. Our coverage area is an unusual geographic market: the Lehigh Valley and Berks County. It's the third largest business district ...

Background Groin injuries represent a considerable problem in male football. Previous groin-specific prevention programmes have not shown a significant reduction in groin injury rates. An exercise ...

The 2026 Pathways Research Explorers online application is now open. Please use the link to Apply Now! Applications close 11:59 pm PST March 6, 2026.